The prognostic significance of serum β2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: Analysis of 1,180 patients

Apostolia Maria Tsimberidou, Hagop M. Kantarjian, Sijin Wen, Susan O'Brien, Jorge Cortes, William G. Wierda, Charles Koller, Sherry Pierce, Mark Brandt, Emil J. Freireich, Michael J. Keating, Elihu H. Estey

Research output: Contribution to journalArticle

Abstract

Purpose: Serum β2 microglobulin (β2M) is prognostic in other hematologic malignancies; therefore, we evaluated its prognostic significance in acute myeloid leukemia (AML). Experimental Design: Multivariate analyses were used to examine the effect of pretreatment serum β2M levels on clinical outcomes in patients with AML. β2M was associated with poorer survival in older but not younger patients. We thus fit separate Cox survival models in patients above and below age 60 years treated with remission induction therapy containing high-dose cytarabine (n = 1,280). In each age group, 50% of the patients were used to develop the model, which was tested in the other 50%. Resampling methods were also used to validate the independent prognostic significance of covariates. Results: In patients 60 years or older (n = 591), poorer risk cytogenetics; poorer performance status; and higher levels of β2M, uric acid, and lactate dehydrogenase were each found to independently predict shorter survival and formed the basis of a scoring system. A similar approach was used in patients younger than 60 years (n = 589), with poorer risk cytogenetics, poorer performance status, older age, higher hemoglobin level, and higher leukocyte count predicting a shorter survival and forming the basis of the scoring system. Higher β2M levels were an adverse independent factor for response, survival, relapse-free survival, and event-free survival in older but not in younger patients. Conclusions: Serum β2M levels can help predict outcome in patients ≥60 years with untreated AML, and their use is strongly encouraged.

Original languageEnglish (US)
Pages (from-to)721-730
Number of pages10
JournalClinical Cancer Research
Volume14
Issue number3
DOIs
StatePublished - Feb 1 2008
Externally publishedYes

Fingerprint

Survival Analysis
Acute Myeloid Leukemia
Serum
Survival
Cytogenetics
Remission Induction
Cytarabine
Hematologic Neoplasms
Uric Acid
Leukocyte Count
L-Lactate Dehydrogenase
Proportional Hazards Models
Disease-Free Survival
Hemoglobins
Research Design
Multivariate Analysis
Age Groups
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The prognostic significance of serum β2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival : Analysis of 1,180 patients. / Tsimberidou, Apostolia Maria; Kantarjian, Hagop M.; Wen, Sijin; O'Brien, Susan; Cortes, Jorge; Wierda, William G.; Koller, Charles; Pierce, Sherry; Brandt, Mark; Freireich, Emil J.; Keating, Michael J.; Estey, Elihu H.

In: Clinical Cancer Research, Vol. 14, No. 3, 01.02.2008, p. 721-730.

Research output: Contribution to journalArticle

Tsimberidou, AM, Kantarjian, HM, Wen, S, O'Brien, S, Cortes, J, Wierda, WG, Koller, C, Pierce, S, Brandt, M, Freireich, EJ, Keating, MJ & Estey, EH 2008, 'The prognostic significance of serum β2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: Analysis of 1,180 patients', Clinical Cancer Research, vol. 14, no. 3, pp. 721-730. https://doi.org/10.1158/1078-0432.CCR-07-2063
Tsimberidou, Apostolia Maria ; Kantarjian, Hagop M. ; Wen, Sijin ; O'Brien, Susan ; Cortes, Jorge ; Wierda, William G. ; Koller, Charles ; Pierce, Sherry ; Brandt, Mark ; Freireich, Emil J. ; Keating, Michael J. ; Estey, Elihu H. / The prognostic significance of serum β2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival : Analysis of 1,180 patients. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 3. pp. 721-730.
@article{4fb2f0f2419449449f9cad1666ab4ac6,
title = "The prognostic significance of serum β2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: Analysis of 1,180 patients",
abstract = "Purpose: Serum β2 microglobulin (β2M) is prognostic in other hematologic malignancies; therefore, we evaluated its prognostic significance in acute myeloid leukemia (AML). Experimental Design: Multivariate analyses were used to examine the effect of pretreatment serum β2M levels on clinical outcomes in patients with AML. β2M was associated with poorer survival in older but not younger patients. We thus fit separate Cox survival models in patients above and below age 60 years treated with remission induction therapy containing high-dose cytarabine (n = 1,280). In each age group, 50{\%} of the patients were used to develop the model, which was tested in the other 50{\%}. Resampling methods were also used to validate the independent prognostic significance of covariates. Results: In patients 60 years or older (n = 591), poorer risk cytogenetics; poorer performance status; and higher levels of β2M, uric acid, and lactate dehydrogenase were each found to independently predict shorter survival and formed the basis of a scoring system. A similar approach was used in patients younger than 60 years (n = 589), with poorer risk cytogenetics, poorer performance status, older age, higher hemoglobin level, and higher leukocyte count predicting a shorter survival and forming the basis of the scoring system. Higher β2M levels were an adverse independent factor for response, survival, relapse-free survival, and event-free survival in older but not in younger patients. Conclusions: Serum β2M levels can help predict outcome in patients ≥60 years with untreated AML, and their use is strongly encouraged.",
author = "Tsimberidou, {Apostolia Maria} and Kantarjian, {Hagop M.} and Sijin Wen and Susan O'Brien and Jorge Cortes and Wierda, {William G.} and Charles Koller and Sherry Pierce and Mark Brandt and Freireich, {Emil J.} and Keating, {Michael J.} and Estey, {Elihu H.}",
year = "2008",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-07-2063",
language = "English (US)",
volume = "14",
pages = "721--730",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - The prognostic significance of serum β2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival

T2 - Analysis of 1,180 patients

AU - Tsimberidou, Apostolia Maria

AU - Kantarjian, Hagop M.

AU - Wen, Sijin

AU - O'Brien, Susan

AU - Cortes, Jorge

AU - Wierda, William G.

AU - Koller, Charles

AU - Pierce, Sherry

AU - Brandt, Mark

AU - Freireich, Emil J.

AU - Keating, Michael J.

AU - Estey, Elihu H.

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Purpose: Serum β2 microglobulin (β2M) is prognostic in other hematologic malignancies; therefore, we evaluated its prognostic significance in acute myeloid leukemia (AML). Experimental Design: Multivariate analyses were used to examine the effect of pretreatment serum β2M levels on clinical outcomes in patients with AML. β2M was associated with poorer survival in older but not younger patients. We thus fit separate Cox survival models in patients above and below age 60 years treated with remission induction therapy containing high-dose cytarabine (n = 1,280). In each age group, 50% of the patients were used to develop the model, which was tested in the other 50%. Resampling methods were also used to validate the independent prognostic significance of covariates. Results: In patients 60 years or older (n = 591), poorer risk cytogenetics; poorer performance status; and higher levels of β2M, uric acid, and lactate dehydrogenase were each found to independently predict shorter survival and formed the basis of a scoring system. A similar approach was used in patients younger than 60 years (n = 589), with poorer risk cytogenetics, poorer performance status, older age, higher hemoglobin level, and higher leukocyte count predicting a shorter survival and forming the basis of the scoring system. Higher β2M levels were an adverse independent factor for response, survival, relapse-free survival, and event-free survival in older but not in younger patients. Conclusions: Serum β2M levels can help predict outcome in patients ≥60 years with untreated AML, and their use is strongly encouraged.

AB - Purpose: Serum β2 microglobulin (β2M) is prognostic in other hematologic malignancies; therefore, we evaluated its prognostic significance in acute myeloid leukemia (AML). Experimental Design: Multivariate analyses were used to examine the effect of pretreatment serum β2M levels on clinical outcomes in patients with AML. β2M was associated with poorer survival in older but not younger patients. We thus fit separate Cox survival models in patients above and below age 60 years treated with remission induction therapy containing high-dose cytarabine (n = 1,280). In each age group, 50% of the patients were used to develop the model, which was tested in the other 50%. Resampling methods were also used to validate the independent prognostic significance of covariates. Results: In patients 60 years or older (n = 591), poorer risk cytogenetics; poorer performance status; and higher levels of β2M, uric acid, and lactate dehydrogenase were each found to independently predict shorter survival and formed the basis of a scoring system. A similar approach was used in patients younger than 60 years (n = 589), with poorer risk cytogenetics, poorer performance status, older age, higher hemoglobin level, and higher leukocyte count predicting a shorter survival and forming the basis of the scoring system. Higher β2M levels were an adverse independent factor for response, survival, relapse-free survival, and event-free survival in older but not in younger patients. Conclusions: Serum β2M levels can help predict outcome in patients ≥60 years with untreated AML, and their use is strongly encouraged.

UR - http://www.scopus.com/inward/record.url?scp=38949093566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949093566&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-2063

DO - 10.1158/1078-0432.CCR-07-2063

M3 - Article

C2 - 18245532

AN - SCOPUS:38949093566

VL - 14

SP - 721

EP - 730

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -